Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Synthetic Human Angiotensin II in Pediatric Patients With Vasodilatory Shock: A Report on Two Patients.

Bailey DM, Chima RS, Tidmarsh GF, Williams MD.

Crit Care Explor. 2019 Aug 15;1(8):e0036. doi: 10.1097/CCE.0000000000000036. eCollection 2019 Aug.

2.

Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock.

Bellomo R, Wunderink RG, Szerlip H, English SW, Busse LW, Deane AM, Khanna AK, McCurdy MT, Ostermann M, Young PJ, Handisides DR, Chawla LS, Tidmarsh GF, Albertson TE.

Crit Care. 2020 Feb 6;24(1):43. doi: 10.1186/s13054-020-2733-x.

3.

LJ000328, a novel ALK2/3 kinase inhibitor, represses hepcidin and significantly improves the phenotype of IRIDA.

Belot A, Gourbeyre O, Fay A, Palin A, Besson C, Latour C, Hopkins CR, Tidmarsh GF, Coppin H, Roth MP, Ritter MR, Hong CC, Meynard D.

Haematologica. 2019 Dec 5. pii: haematol.2019.236133. doi: 10.3324/haematol.2019.236133. [Epub ahead of print]

4.

Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial.

Ham KR, Boldt DW, McCurdy MT, Busse LW, Favory R, Gong MN, Khanna AK, Chock SN, Zeng F, Chawla LS, Tidmarsh GF, Ostermann M.

Ann Intensive Care. 2019 Jun 3;9(1):63. doi: 10.1186/s13613-019-0536-5.

5.

Broad spectrum vasopressors: a new approach to the initial management of septic shock?

Chawla LS, Ostermann M, Forni L, Tidmarsh GF.

Crit Care. 2019 Apr 16;23(1):124. doi: 10.1186/s13054-019-2420-y.

6.

Therapeutic Opportunities for Hepcidin in Acute Care Medicine.

Chawla LS, Beers-Mulroy B, Tidmarsh GF.

Crit Care Clin. 2019 Apr;35(2):357-374. doi: 10.1016/j.ccc.2018.11.014. Epub 2019 Jan 30. Review.

7.

The authors reply.

Bellomo R, Kroll S, Chawla LS, Tidmarsh GF.

Crit Care Med. 2019 Mar;47(3):e271-e272. doi: 10.1097/CCM.0000000000003601. No abstract available.

PMID:
30768522
8.

Angiotensin converting enzyme defects in shock: implications for future therapy.

Chawla LS, Chen S, Bellomo R, Tidmarsh GF.

Crit Care. 2018 Oct 28;22(1):274. doi: 10.1186/s13054-018-2202-y. No abstract available.

9.

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II.

Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW, Ham KR, Kashani K, Szerlip HM, Prowle JR, Bihorac A, Finkel KW, Zarbock A, Forni LG, Lynch SJ, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Bellomo R; Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators.

Crit Care Med. 2018 Jun;46(6):949-957. doi: 10.1097/CCM.0000000000003092. Erratum in: Crit Care Med. 2018 Aug;46(8):e824.

10.

Angiotensin II for the Treatment of Vasodilatory Shock.

Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, McCurdy MT, Boldt DW, Chock S, Young PJ, Krell K, Wunderink RG, Ostermann M, Murugan R, Gong MN, Panwar R, Hästbacka J, Favory R, Venkatesh B, Thompson BT, Bellomo R, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Deane AM; ATHOS-3 Investigators.

N Engl J Med. 2017 Aug 3;377(5):419-430. doi: 10.1056/NEJMoa1704154. Epub 2017 May 21.

11.

Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial.

Chawla LS, Russell JA, Bagshaw SM, Shaw AD, Goldstein SL, Fink MP, Tidmarsh GF.

Crit Care Resusc. 2017 Mar;19(1):43-49.

PMID:
28215131
12.

End-tidal carbon monoxide and hemolysis.

Tidmarsh GF, Wong RJ, Stevenson DK.

J Perinatol. 2014 Aug;34(8):577-81. doi: 10.1038/jp.2014.66. Epub 2014 Apr 17. Review.

PMID:
24743136
13.

Pharmacodynamic evaluation of intragastric pH and implications for famotidine dosing in the prophylaxis of non-steroidal anti-inflammatory drug induced gastropathy-a proof of concept analysis.

Kent JD, Holt RJ, Jung D, Tidmarsh GF, Grahn AY, Ball J, Peura DA.

J Drug Assess. 2014 Feb 17;3(1):20-7. doi: 10.3109/21556660.2014.895371. eCollection 2014.

14.

Bridging the gap between basic and applied biology: towards preclinical translation.

Cagan RL, Justice MJ, Tidmarsh GF.

Dis Model Mech. 2013 May;6(3):559-61. doi: 10.1242/dmm.012450.

15.
16.

A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo.

Ammons WS, Wang JW, Yang Z, Tidmarsh GF, Hoffman RM.

Neoplasia. 2007 Aug;9(8):625-33.

17.

A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma.

Chiorean EG, Dragovich T, Hamm J, Langmuir VK, Kroll S, Jung DT, Colowick AB, Tidmarsh GF, Loehrer PJ.

Cancer Chemother Pharmacol. 2008 May;61(6):1019-26. Epub 2007 Jul 28.

PMID:
17661038
18.

2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo.

Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ.

Cancer Res. 2004 Jan 1;64(1):31-4.

19.

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, Wahl RL, Knox SJ, Vose JM.

J Clin Oncol. 2001 Oct 1;19(19):3918-28.

PMID:
11579112
20.

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.

Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, Zelenetz AD, Tidmarsh GF, Stagg RJ, Kaminski MS.

J Clin Oncol. 2000 Mar;18(6):1316-23.

PMID:
10715303
21.

Identification of a novel bone marrow-derived B-cell progenitor population that coexpresses B220 and Thy-1 and is highly enriched for Abelson leukemia virus targets.

Tidmarsh GF, Heimfeld S, Whitlock CA, Weissman IL, Müller-Sieburg CE.

Mol Cell Biol. 1996 Oct;16(10):5946. No abstract available.

22.
23.

The early B lineage antigen BP-1 and the transformation-associated antigen 6C3 are on the same molecule.

Wu Q, Tidmarsh GF, Welch PA, Pierce JH, Weissman IL, Cooper MD.

J Immunol. 1989 Nov 15;143(10):3303-8.

PMID:
2809203
25.

Maturation of hematolymphoid cells that express Thy-1.

Müller-Sieburg CE, Tidmarsh GF, Weissman IL, Spangrude GJ.

Immunol Ser. 1989;45:289-316. Review. No abstract available.

PMID:
2577321
26.

A new lymphocyte-specific gene which encodes a putative Ca2+-binding protein is not expressed in transformed T lymphocyte lines.

Jongstra J, Tidmarsh GF, Jongstra-Bilen J, Davis MM.

J Immunol. 1988 Dec 1;141(11):3999-4004.

PMID:
3263441
27.

The in vitro translation product of the murine lambda 5 gene contains a functional signal peptide.

Jongstra J, Jongstra-Bilen J, Tidmarsh GF, Davis MM.

Mol Immunol. 1988 Aug;25(8):687-93.

PMID:
2460755
28.
29.

Bone marrow stromal cell lines with lymphopoietic activity express high levels of a pre-B neoplasia-associated molecule.

Whitlock CA, Tidmarsh GF, Muller-Sieburg C, Weissman IL.

Cell. 1987 Mar 27;48(6):1009-21.

PMID:
3493849
30.

Expression of the 6C3 antigen on murine hematopoietic neoplasms. Association with expression of abl, ras, fes, src, erbB, and Cas NS-1 oncogenes but not with myc.

Morse HC 3rd, Tidmarsh GF, Holmes KL, Frederickson TF, Hartley JN, Pierce JH, Langdon WY, Dailey MO, Weissman IL.

J Exp Med. 1987 Mar 1;165(3):920-5.

32.
33.

Rapid release of iron from ferritin by siderophores.

Tidmarsh GF, Klebba PE, Rosenberg LT.

J Inorg Biochem. 1983 Apr;18(2):161-8.

PMID:
6222161

Supplemental Content

Loading ...
Support Center